AZN : Analysis & Opinions

  1. New York AG Opens Exxon-Mobile Investigation, AstraZeneca to ...

    November 6, 2015
    New York state attorney general Eric Schneiderman announced yesterday that he would be launching an investigation into energy ...
  2. Pfizer CEO: The Story Behind Ian Read

    June 3, 2015
    Learn about the rise of Ian Read, the CEO of Pfizer. Pfizer is one of the most profitable and largest pharmaceutical companies ...
  3. Amgen Takes a Hit, Shelves Potential Blockbuster

    May 29, 2015
    Amgen's (NASDAQ: AMGN) investors learned this past week that the company is walking away from its deal with AstraZeneca (NYSE: ...
  4. Houston, Johnson & Johnson May Have a Problem

    May 19, 2015
    When it comes to potential "safe haven" investments, healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is often ...
  5. 3 Top Pharma Stocks that Pay Regular Dividends

    May 1, 2015
    The low down on three big name, dividend-paying pharma stocks.
  6. How the UK Makes Money

    April 29, 2015
    The United Kingdom has one of the strongest economies in the world thanks to the strength of its services, manufacturing ...
  7. How China Makes Money

    April 28, 2015
    China has the first or second largest GDP in the world but is not nearly as developed as others in the top 10.
  8. Johnson & Johnson's New Billion-Dollar Blockbuster

    April 17, 2015
    Invokana, one of Johnson & Johnson's (NYSE: JNJ) newest drugs, was a bright spot in the company's otherwise lackluster ...
  9. Johnson & Johnson Earnings: 5 Key Things to Watch

    April 10, 2015
    Earnings season is readying to kick off in a big way, and within the health care sector most eyes are beginning to shift ...
  10. Interested In Pharmaceutical Stocks? Try Novartis (ADR)

    February 26, 2015
    Novartis AG, is the world's leading pharmaceutical company by sales. Here is a closer look at Novartis, and how its financials ...
  11. How To Profit From These 3 Overvalued Sectors

    January 22, 2015
    Flea markets crack me up. Most of the vendors seem like they cleaned the junk from their garage and assigned an arbitrary, ...
  12. An Investing Legend Predicts A Major M&A Boom -- Here's How To ...

    August 7, 2014
    Some high-profile buyout deals have been falling apart lately. For instance, the third largest U.S. wireless carrier Sprint ...
  13. What Are The Best Bets In Biotech?

    May 2, 2014
    The NASDAQ Biotechnology Index is off nearly 20% as its components busy themselves with hostile bids and frenzied buying ...
  14. The United Kingdom Is Ripe For Stock Pickers

    December 6, 2013
    With the situation in Europe finally moving ahead, investors may want to focus on the United Kingdom. Stocks within the nation ...
  15. Yet Another Failure Has Rigel Pharmaceuticals Almost Back To ...

    August 26, 2013
    Rigel sees yet another clinical failure from its pipeline.
  16. AstraZeneca Goes Back To The M&A Well Yet Again

    August 26, 2013
    AstraZeneca's acquisition of Amplimmune could pay big dividends in a decade.
  17. Will Immunotherapy Disrupt The Oncology Market?

    August 20, 2013
    Immunotherapy could radically change the treatment of cancer, and the revenue opportunities for pharmaceutical companies.
  18. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

    July 31, 2013
    Amgen is beating growth targets today, but fears about generics and a dull pipeline concern investors.
  19. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  20. AstraZeneca Pays Up To Patch Up Another Key Area

    June 10, 2013
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  21. AstraZeneca Looks To Fish Oil To Round Out Its Cardio Portfolio

    May 28, 2013
    AstraZeneca validates the purified fish oil concept, but not at an especially high price.
  22. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  23. The Winners And Losers Of QE3

    November 15, 2012
    The market is a mix of winners and losers. When one side profits, the other side suffers.
  24. Blue Chip Stocks Paying The Highest Dividends

    October 25, 2012
    While picking individual stocks is risky, these blue chip companies have histories that show they can be good choices.
  25. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally.
  26. UK's Global Footprint Stocks

    June 27, 2012
    Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.
  27. AstraZeneca Searches For Answers

    May 3, 2012
    AstraZeneca has an opportunity to do something big when it brings in a new CEO.
  28. The Costs Of Being Obese

    May 2, 2012
    Numbers released by the Mayo Clinic suggest obesity costs more than smoking.
  29. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  30. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  31. The War Against Alzheimer's Requires Thinking Small

    January 2, 2012
    A meaningful treatment for Alzheimer's is no longer out of reach. Find out which companies are in the race to find a cure.
  32. The Contrarian Play In Europe

    October 26, 2011
    Nothing could be bolder than adding European stocks to a portfolio. Europe offers a fertile ground for contrarian investors.
  33. The Overlooked Dental Health Sector

    August 25, 2011
    While health care remains a great long-term portfolio position, many investors ignore the dental sub-sector. However, benefiting ...
  34. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  35. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  36. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  37. Glaxo And Human Genome Find Rare FDA Success

    March 10, 2011
    With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
  38. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  39. The Future of Stem Cells

    June 15, 2010
    Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
  40. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  41. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount.
  42. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  43. An ETF To Play The U.K.

    January 13, 2010
    For investors who simply seek broad exposure to the overall U.K. economy, EWU may be your best bet.
  44. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  45. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  46. 5 Stocks With Low P/Es And High Dividends

    June 19, 2009
    Finding undervalued gems can help boost porfolio returns. Check out five potential diamonds in the rough.
Trading Center